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Introduction 
Pulmonary metastases are a common occurrence in patients 
with extrathoracic cancer. Our goal in this chapter is to 
explore the complex processes of metastasis and why there 
is a predisposition for this to occur in the lung. In addition, 
we aim to describe the incidence of pulmonary metastases 
in various contexts and based on the origin of the primary 
tumor.
Pathophysiology
The process of metastatic spread involves many complex 
events. The pathophysiology of pulmonary metastasis 
is initiated with the growth, neovascularization, and 
tissue invasion of the primary tumor. Subsequently, 
there is detachment of cells from the primary tumor and 
hematogenous dissemination where these cells may arrest 
and proliferate in capillary beds. After surviving host 
defense mechanisms, the tumor cells extravasate into larger 
arteries and extend into organs by adhering to the basement 
membrane (1). There are many host-factors that must act 
in concert for this process to occur, including cell adhesion 
molecules, motility, growth and angiogenesis factors and 
various cytokines (2,3).
There are unique characteristics of the pulmonary system 
that make metastases more likely to occur in the lung than 
anywhere else in the body. Schueller et al. describe these 
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features well, “The lungs receive the entire cardiac output 
every minute. They also have the densest capillary bed 
in the body and are the first capillary plexus that most of 
the lymphatic drainage meets after entering the venous 
system. In addition, the lungs consist of a meshwork of 
delicate membranes that easily entrap tumor cells which can 
readily draw on nearby oxygenated air for sustenance.” (4). 
These characteristics provide an ideal situation and 
environment for the cascade of events to occur that lead to 
metastases in the lung. The rate of growth of metastases 
was studied by Spratt et al. They performed a radiographic 
study of 118 patients with untreated pulmonary metastases 
and demonstrated, through mathematical calculation and 
radiographic correlation, that the rate of growth of the 
pulmonary metastases was exponential (5).
There are multiple routes of metastasis to the lung from 
extra thoracic tumors. Certain groups of extrathoracic 
tumors have characteristic patterns of spread attributed to 
the unique and complex series of events that must occur 
for metastasis to succeed. The most common route of 
metastasis is a hematogenous mechanism. This pattern of 
spread is first initiated with detachment of cells from the 
primary tumor and hematogenous dissemination of the cells 
into pulmonary capillary beds. A minority of these cells 
will survive host defense mechanisms and penetrate the 
pulmonary interstitium, leading to metastatic growth (6). 
It is also possible for the pulmonary vasculature to be 
seeded at the same time as dissemination in other capillary 
beds such as the liver, bone or brain. In addition, there are 
situations where hematogenous spread occurs only after 
other capillary beds have been seeded, such as prostate 
or breast cancer. Metastatic spread can also occur via 
lymphatic channels—regional lymph nodes become the site 
of collection, which commonly occurs with endobronchial 
metastases (7).
As previously described, pulmonary metastasis is a 
complex process of tumor cell dissemination from the 
primary tumor to the lungs. There are currently two major 
concepts of metastasis that may influence the approach 
of clinicians (8). Fidler et al. describes a theory of late 
dissemination of metastases. This is postulated to occur 
after genetic changes to the primary tumor and surrounding 
environment have occurred that are sufficient for migration 
and spread (9). A different theory suggests metastasis occurs 
via early dissemination. Morgan et al. describes a process of 
early shedding of single cancer cells. There is a subsequent 
dormant stage where the cells may acquire genetic and 
environmental alterations that trigger proper metastasis and 
lead to delayed recurrence (10). Both theories of metastasis 
may occur separately or together within different tumor 
types and individuals—rendering the genetic composition 
and characteristics of pulmonary metastases unique and 
complex to treat.
For lung metastases to grow, adequate nutrition is 
needed via a viable blood supply. In the lung, there are 
three possible routes: bronchial circulation, pulmonary 
circulation, or both. The route of blood supply to the 
metastases is important as it can be a means of therapeutic 
intervention. Historically, it was held that most lung tumors 
are supplied by bronchial circulation and that pulmonary 
“neovascularization” did not occur (11-13). However, 
Milne et al. conducted a computer topographic angiography 
study of resected human lungs with pulmonary metastases 
of varying origin which demonstrated that angiogenesis 
does occur. In addition, there was a pulmonary circulation 
component in all metastases usually supplying the lateral 
portion of the tumor (14). The vascularization of pulmonary 
metastases is variable and complex, often recruiting supply 
from bronchial and pulmonary origin. 
Interestingly, diet may also have a role in tumor growth. 
Hayman et al. details a study that has shown how a diet high 
in omega-6 fatty acids has been linked to statistically higher 
rates of visible lung metastases in mice injected with human 
breast cancer cells. As well, omega-3 fatty acids have been 
shown to reduce lung metastases in colorectal cancer, breast 
carcinoma, and melanoma (15). This is postulated to be 
due to influences on gene expression which can affect the 
production of various protein factors.
There are many biochemical factors in the tumor 
microenvironment that play a key role in the development 
of lung metastases. Laboratory studies have shown that 
cellular factors such as vascular endothelial growth factor 
(VEGF), interleukin-8 (IL-8), platelet-derived endothelial 
cell growth factor (PD-ECGF), and/or basic fibroblast 
growth factor (bFGF) play an important role in the tumor 
microenvironment (16). As well, tumor cells have a role 
in metastatic invasion with very late antigen 4 (VLA-4) 
production from hematopoietic progenitor cells. This 
production of VLA-4 allows for interaction with fibronectin 
in fibroblasts at premetastatic sites (17). Chemokines are 
activated by tumor cells through the attraction of immune 
cells and tumor cells to the lungs via VEGF-A, tumor 
necrosis factor-α (TNF-α), and transforming growth factor–
β (TGF-β) inducing expression of inflammatory chemokines 
used for lung invasion (18). Once tumor cells are at the site 
of metastasis, they can anchor to the environment through 
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surface expression of intercellular adhesion molecule 1 
(ICAM-1) induced be recruited neutrophils (19). Cellular 
expression of proteins that enhance anchoring, recruitment 
of cells and invasion are necessary for lung metastasis.
Epidemiology
The lung is the most common site for cancer metastases. 
In addition, that most common malignant tumors found 
in the lung are metastases from extrathoracic tumors 
(4,20). Studies vary widely in reported rates of pulmonary 
metastases due to differences in clinical study design 
such as tumor type, the time period from primary tumor 
to pulmonary metastases, and the type and frequency of 
imaging used to detect them. This time period can be 
significant as it has been shown that pulmonary metastases 
have been described up to 15 years after primary cancer 
detection (6). It is commonly accepted that up to half of 
autopsies performed on patients who died of malignancy 
have pulmonary metastases (21,22). Regardless of the 
high amount of reported lung metastases in patients with 
cancer, only 15% to 20% develop clinical symptoms such 
as cough or nonspecific chest pain from metastases (15). 
Van Meerbeeck et al. combined data from multiple autopsy 
series to describe the cumulative incidence of pulmonary 
metastases for non-pulmonary types of cancer (Table 1) (23). 
This shows a high incidence in urogenital and intestinal 
origin likely due to the cancer distribution of the 
population. Detterbeck et al. conducted a surgical series of 
6,732 patients describing the incidence of primary cancer 
types with resected pulmonary metastases (Table 2) (24). 
These resected metastases were presumed “solitary” 
or “unique” by available staging techniques and reflect 
a more clinically meaningful distribution of identified 
Table 1 Incidence and cumulative incidence of pulmonary metastases° in various non-pulmonary cancer type
Tumor type Incidence at diagnosis (%)* Cumulative Incidence (%)**
Frequency of metastases restricted  
to the lungs (%)***
Osteosarcoma NA 38–95 NA
Soft tissue sarcoma 66
Renal cell carcinoma 55–75
Testicular cancer 20–30 40–50 <5
Head and neck cancer NA 12–41 NA
Colorectal cancer 14 2–4
Pancreatic cancer 40 0
Hepatocellular cancer 37–70 NA
Uterine cancer 5 1
Cervical cancer 10–20 25
Ovarian cancer 28 0
Breast 5 10–15
Melanoma 48 70 10
Thyroid cancer NA 10–25 NA
Adrenocortical cancer 71
Choriocarcinoma 60 NA
Prostate <1 25 0
Overall 20 20–50 NA
°, pulmonary parenchymal metastases; *, expressed as percentage of patients presenting with the specific tumor type; **, expressed as 
percentage of patients with the specific tumor type; ***, expressed as percentage of patients with metastases restricted to the lung (without 
metastases elsewhere).
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pulmonary metastases. The most common sites were 
thyroid, colon, breast, genitourinary tract, skin, liver, breast, 
and adrenal glands. However, this study was biased due to 
“resectability”—pulmonary metastases from colon cancer 
may be resectable whereas systemic spread of prostate 
cancer is usually unresectable and therefore not reflected in 
this study. In summary, there are multiple ways to describe 
the incidence of pulmonary metastases, which varies due to 
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